Email this article 
Tacrolimus in moderate and severeatopic dermatitis treatment. The first clinical experience in Russia
- Authors: Elisyutina O.G.1, Fedenko ES1, Shtyrbul OV1, Niyazov DD1, Elisyutina OG2, Fedenko ES2, Shtyrbul OV2, Niyazov DD2
-
Affiliations:
- Institute of Immunology
- Issue: Vol 8, No 6 (2011)
- Pages: 68-76
- Section: Articles
- Submitted: 10.03.2020
- Published:
- URL: https://rusalljournal.ru/raj/article/view/822
- DOI: https://doi.org/10.36691/RJA822
- ID: 822
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
Methods. There were 19 moderate and 11 severe AD patients under supervision. Treatment with tacrolimus ointment 0,1% was started with twice a day application. Duration of this treatment was from 1 to 4 weeks (18±4,2 days) up to skin clearance. When symptoms were reduced, the frequency of tacrolimus application was reduced as well to once a day daily, and than to twice a week. Generally, improvement was observed within one week of treatment. Clinical efficiency was assessed by SCORAD index and Investigators' Global Assessment (IGA). Results. Positive clinical effect of tacrolimus 0,1% ointment therapy was found in 90% of AD patients resulted in significant reduction of dryness, rushes, skin itch, SCORAD and IGA indexes.
Conclusion. Tacrolimus 0,1% ointment is effective and safe for treatment of severe and moderate AD. It should be applied both as exacerbations treatment and as maintenance therapy in AD patients.
About the authors
Ol'ga Gur'evna Elisyutina
Email: el-olga@yandex.ru
E S Fedenko
O V Shtyrbul
D D Niyazov
O G Elisyutina
Institute of ImmunologyInstitute of Immunology
E S Fedenko
Institute of ImmunologyInstitute of Immunology
O V Shtyrbul
Institute of ImmunologyInstitute of Immunology
D D Niyazov
Institute of ImmunologyInstitute of Immunology
References
- Аллергология и иммунология: национальное руководство. Под ред. Р.М.Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2009, 656 с.
- Akdis C.A. Review article Diagnosis and treatment of atopic dermatitis in children and adults: Europian Academy of Allergology and Clinical Immunology. American Academy of Allergy, Asthma and Immunology. PRACTALL Consensus report. Allergy. 2006, v. 61, p. 969-987.
- Hengge U.R., Ruzicka T., Schwartz R.A., Cork M.J. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 2006, v. 54(1), p. 1-15.
- Liu J., Farmer J.D. Jr., LaneW.S. et al. Calcineurin is a com mon target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 1991, v. 66, p. 807-815.
- Ashcroft D.M., Chen L.C., Garside R. et al. Topicalpimecrolimus for eczema. Cochrane Database of Systematic Reviews. 2007, Issue 4.
- Hebert A.A. Review of pimecrolimus cream 1% forthe treat ment of mild to moderate atopic dermatitis. Department of Dermatology, The University of Texas Health Science Center, Houston, Texas 77030, USA.
- Sheng-Li Chen. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: A metaanalysis of randomized clinical trials. Journal of Dermatological Treatment. 2010, v. 21, p. 144-156.
- Reitamo S. et al. Treatment with twice-weekly tacrolimus ointment in patients with moderate to severe atopic dermatitis: results from two randomized, multicenter, comparative studies. Journal of Dermatological Treatment. 2010, v. 21, p. 34-44.
- Kyllonen H., Remitz A., Mandelin J.M.et al. Effects of 1-year intermitted treatment with topical tacrolimus monotherapy on skin collagen synthesis in patient with atopic dermatitis. Br. J. of Dermatology. 2004, v. 150, p. 1174-1181.
- Hanifin J.M., Rajka G. Diagnostic features of atopic dermatitis. Acta Derm. Venerol. 1980, v. 92, p. 44-47.
- Europian Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology. 1993, v. 186, p. 23-31.
Supplementary files
